New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 11, 2017 – The FDA announced the discontinuation of ViiV Healthcare’s Rescriptor (delavirdine mesylate) 100 mg and 200 mg tablets due to business reasons.
Download PDF
Return to publications
